DiFusion said today that it won FDA 510(k) clearance for its Xiphos-ZF spinal interbody device, the first spinal implant developed from the biomaterial Zfuze. Zfuze is a new biomaterial that is said to elicit pro-reparative M2 macrophage response and significant reductions in Interleukin 1-Beta and Interleukin 6. Both IL1-Beta and IL6 are cytokine markers for prolonged […]
DiFusion Technologies said it secured CE Mark approval in the European Union for its CleanFuze antimicrobial spine implant line.
Georgetown, Texas-based DiFusion said the CleanFuze devices are designed to reduce surgical site infections using its antimicrobial orthobiologic polymer.